IJRETINA International Journal of Retina最新文献

{"title":"RETINAL IMPAIRMENT ASSOCIATED WITH LONG-TERM USE OF RITONAVIR AMONG HIV PATIENTS: A SYSTEMATIC REVIEW FOR PRIMARY EYE CARE PRACTICE","authors":"Zakirunallah - Karunia, Ivana Beatrice Alberta, Salsha Alyfa Rahmani","doi":"10.35479/ijretina.2022.vol005.iss001.179","DOIUrl":"https://doi.org/10.35479/ijretina.2022.vol005.iss001.179","url":null,"abstract":"Introduction: Ritonavir as part of Highly Active Antiretroviral Therapy (HAART) is a potent inhibitor of HIV protease that have been reported causing retinal impairment in the long term use. Primary eye care (PEC) is an integral part of primary health care that provides an early screening for drug induced retinal toxicity, by using a funduscopy examination. This study proposed to review and analyze some case reports conducted on long-term use of ritonavir that affects retinal impairment among HIV patients, in primary eye care practice. \u0000Methods: PubMed and Google Scholar were used to perform a systematic review of retinal impairment associated with long-term use of ritonavir among HIV patients. Using PRISMA 2020 Guidelines, nine case reports and one case series were included in this review. \u0000Result: Funduscopy mainly showed bilateral Retinal Pigment Epithelium (RPE) atrophy with hypertrophy or mottling. Two cases found bilateral crystalline deposits with pigment disruption. One case showed rounded hypopigmented lesion. Bilateral subtle annular pattern of RPE was found in one case. Bilateral retinitis pigmentosa-like appearance found in one case while another found unilateral hyperemic lesion at the left fovea. \u0000Conclusion: Retinal impairment detected on funduscopy occurred in HIV patients on long-term use of ritonavir.","PeriodicalId":33128,"journal":{"name":"IJRETINA International Journal of Retina","volume":"6 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-02-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87215325","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"THE ASSOCIATION BETWEEN DURATION OF SILICONE OIL TAMPONADE AND RETINAL REDETACHMENT AFTER SILICONE OIL REMOVAL: A SYSTEMATIC REVIEW AND META-ANALYSIS","authors":"A. Victor, Enzo Sapuandi, R. Pranata","doi":"10.35479/ijretina.2022.vol005.iss001.183","DOIUrl":"https://doi.org/10.35479/ijretina.2022.vol005.iss001.183","url":null,"abstract":"Background: Silicone oil (SO) removal following vitrectomy and injection of silicone oil may cause retinal redetachments (re-RD), with duration of tamponade being considered as the risk factor. So, we wanted to evaluate the duration of silicone oil tamponade as a risk factor of retinal redetachments after silicone oil removal. \u0000Result: Ten studies comprising of 2120 eyes were included in this review. Pooled analysis showed no statistically significant difference between the re-RD group and the non-re-RD group in terms of SO duration (mean difference -1.87 months; 95% CI, -3.87 to 0.13; p=0.07; I2=53.1%). The re-RD rate did not differ between the shorter and longer duration of SO tamponade (OR=1.44; 95% CI, 0.54 to 3.82; p=0.47; I2: 63.3%). \u0000Conclusion: The duration of SO tamponade was not associated with re-RD after SO removal.","PeriodicalId":33128,"journal":{"name":"IJRETINA International Journal of Retina","volume":"53 1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-02-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86779545","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CLINICAL PROFILE AND VISUAL OUTCOME AFTER ERM REMOVAL- AN EXPERIENCE FROM A TERTIARY CARE REFERRAL CENTER IN NORTH INDIA","authors":"Shabnum Nabi Var, Perveiz Ahmad Handoo","doi":"10.35479/ijretina.2022.vol005.iss001.184","DOIUrl":"https://doi.org/10.35479/ijretina.2022.vol005.iss001.184","url":null,"abstract":"Introduction: ERM is a cellular proliferation on the inner retinal surface and possesses contractile properties which leads to variable visual symptoms. \u0000Method: Thirty-four patients affected with epiretinal membrane were enrolled in this study. All patients underwent standard three port pars plana vitrectomy using standard 23-gauge instruments. Both ERM and ILM peels were performed in a circumferential pattern around the fovea. Patients were followed for 6 months. The visual outcome measures included postoperative logMAR visual acuity. The anatomical outcome was measured as decrease in foveal thickness on spectral domain optical coherence tomography (SD-OCT). Perioperative factors including duration of symptoms, preoperative visual acuity, etiology, membrane type and leakage on fundus fluorescein angiogram were correlated with the final visual outcomes. \u0000Results: The mean age of the patients in this study was 60.25  17.5 years with a range of 16 to 80 years. 19 patients (56%) were males. 33 patients had a unilateral ERM and 1 patient had an ERM in both eyes. Diminution of vision was the most common symptom in 34 patients, distortion of vision (metamorphopsia) was seen in 20 (58.8%) patients. The mean pre-operative log MAR best corrected visual acuity (BCVA) was 1.4±0.77 and the mean post-operative log MAR best corrected visual acuity (BCVA) was 0.9 ±0.63. Out of 34 patients in our study, 31 (91.2%) had improvement in VA, and the remaining 3 (8.82%) patients had no improvement and none of the patients had decreased vision. 16 patients had ≥2 lines of improvement in visual acuity. 15 patients had less than 2 lines of improvement. \u0000Conclusion: ERMs pose a significant risk to compromise the vision and affect varied age groups. ERM removal through standard three port pars plana vitrectomy offers an effective and safe procedure with better post operative visual outcomes.","PeriodicalId":33128,"journal":{"name":"IJRETINA International Journal of Retina","volume":"42 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-02-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82677332","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"MANAGEMENT OF LARGE IDIOPATHIC MACULAR HOLE WITH PARS PLANA VITRECTOMY AND MODIFIED MINIMAL ILM PEELING WITH SUPERIOR ILM FLAP","authors":"Fatimah Syakirah, Ramzi Amin, Abdul Karim Ansyori","doi":"10.35479/ijretina.2022.vol005.iss001.189","DOIUrl":"https://doi.org/10.35479/ijretina.2022.vol005.iss001.189","url":null,"abstract":"Introduction: Idiopathic macular hole is an anatomic discontinuity of the neurosensory retina in the center of the macula or fovea resulted from tractional forces on the foveola at the vitreoretinal interface not associated with other causes. Diagnosis and management of this condition requires expertise, skills, and specialized examination to detect changes in the retina which is important for deciding the appropriate management. \u0000Case Report: We report a case of 66-year-old man with idiopathic macular hole (IMH) in the right eye with initial best corrected visual acuity (BCVA) 20/1200. Fundus examination and optical coherence tomography (OCT) confirmed the presence of large full thickness macular hole with mean linear diameter 673 µm and posterior hyaloid still attached to the optic nerve. The patient was managed with pars plana vitrectomy (PPV) surgery using modified minimal internal limiting membrane (ILM) peeling with superior ILM flap and SF6 gas tamponade. Two weeks after surgery OCT showed closure of the macular hole. BCVA at two and four weeks after surgery improved to 20/240 and 20/200 respectively. \u0000Discussion: PPV with ILM peeling is one of the standardized procedures in IMH surgery. Failure of the vitrectomy surgery to close the macular hole or late reopening of initially successfully closed holes may occur without removal of the ILM due to ILM role as a scaffold for cellular proliferation or attachment of contractile tissue that may cause persistent vitreomacular traction. Variations of ILM peeling such as inverted ILM peeling has been used to improve closure rate for large IMH and has showed favorable results both anatomically and functionally. Nowadays, to avoid or minimize the damage of retinal microstructure by ILM peeling, some surgeons introduced new techniques aiming to preserve the ILM for IMH. Minimal ILM peeling with superior ILM flap technique in this case was done to obtain MH closure with less microstructural retinal abnormalities and better visual outcomes. \u0000Conclusion The management of large IMH with PPV and modified minimal ILM peeling with superior ILM flap in this case showed good results in terms of anatomic and functional outcomes.","PeriodicalId":33128,"journal":{"name":"IJRETINA International Journal of Retina","volume":"25 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-02-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88410324","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence of Advanced Diabetic Eye Disease among diabetic patients in a tertiary care hospital in South India","authors":"Ksheeraja Y, Ramya M","doi":"10.35479/ijretina.2022.vol005.iss001.178","DOIUrl":"https://doi.org/10.35479/ijretina.2022.vol005.iss001.178","url":null,"abstract":"Introduction:To analyze the  Prevalence of advanced diabetic eye disease(ADED) among diabetic patients \u0000Methods:This was a  prospective cross-sectional study in a tertiary care hospital. A total of 1650 patients with a history of type 2 diabetes who visited ophthalmology department were enrolled in study. History regarding  socioeconomic status, literacy level, duration of diabetes, comorbidities, medications, HbA1c levels were analyzed. Visual acuity,Slit-lamp, fundus examination were done.Medical/surgical intervention was done to restore vision. \u0000Results: A total of  1650 patients with a history of type 2 diabetes were analyzed. Among them 327 patients had fundus changes of diabetic retinopathy, hence the prevalence of DR among diabetics was 19.81%. Out of 327 patients, 53 patients had advanced diabetic eye disease and the prevalence of ADED among Diabetics was 3.20%. The mean age of the patients was 50.91+/- 9.06years.There were 42 (79.24%)males and 11 (20.7%)females.24 (45.28%)patients had vision of 6/6 - 6/60, 28 (52.83%|) patients had vision 5/60-CFCF.15(28.30%) patients had PDR with vitreous hemorrhage.12 patients (22.64%) had PDR with subhyaloid hemorrhage,11 patients (20.75%) had PDR with FVP sparing macula,13 patients(24.52%) had PDR with FVP involving the macula,2 patients(3.77 %) had  PDR with Neovascular glaucoma.34 patients (64.15%) underwent PRP,19 patients (35.84 %) needed surgical intervention. \u0000Conclusion: This study shows that the prevalence of diabetic retinopathy among diabetic patients was 19.81%. The prevalence of Advanced Diabetic Eye Disease among diabetic patients was 3.2%. Hence Effective implementation of primary, secondary and tertiary prevention strategies has the potential to significantly reduce blindness due to DR.","PeriodicalId":33128,"journal":{"name":"IJRETINA International Journal of Retina","volume":"197 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-02-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87812018","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CLINICAL CHARACTERISTICS OF VITRECTOMY PATIENTS IN THE CASE OF RHEGMATOGEN RETINA DETACHMENT IN PROF DR R D KANDOU CENTRAL GENERAL HOSPITAL, MANADO","authors":"A. Nursalim, Vera Sumual, Eugeni Jumilia Rachel Sumanti, Irene Rumampuk, C. M. Komaling, S. J. Loho","doi":"10.35479/ijretina.2022.vol005.iss001.188","DOIUrl":"https://doi.org/10.35479/ijretina.2022.vol005.iss001.188","url":null,"abstract":"Abstract \u0000Introduction \u0000Rhegmatogenous retinal detachmet (RRD) is an ophthalmology urgency that can cause blindness if treated late. Incidence of RRD has increasing overtime. We describe the clinical characteristics of vitrectomy patients in RRD cases at prof dr R D Kandou hospital, north Sulawesi Province, Manado City, Indonesia. \u0000Method \u0000The study was conducted based on a retrospective search on the medical record data of 72 RRD patients who underwent vitrectomy in the period June 2018-2020. \u0000result \u0000The most gender was male as many as 43 patients (59.70%), the most age were in the 51-60 years range as many as 33 patients (45.83%), the eyes affected by RRD were mostly right eyes as many as 41 patients (56, 9%), the location of the break was mostly in the superotemporal area as many as 28 (38.9%), the status of the macula was mostly macular off as many as 44 patients (61.10%), the anesthesia used was local anesthesia in 69 patients (95.80 %), the time taken for the procedure was more than 1 month for all patients. \u0000conclusion \u0000The clinical characteristics of RRD patients at Prof dr R D Kandou Hospital are in line with trends in several places in the world. Time to do vitrectomy need to be evaluated and corrected to improve visual prognosis. \u0000 ","PeriodicalId":33128,"journal":{"name":"IJRETINA International Journal of Retina","volume":"33 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-02-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76665021","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multifocal Electroretinogram, Central Macula Thickness and Visual Acuity in Diabetic Macular Edema Following Intravitreal Injection of anti-VEGF","authors":"S. Nusanti, Kirana Sampurna, A. Djatikusumo, A. Yudantha, J. Prihartono","doi":"10.35479/ijretina.2021.vol004.iss002.156","DOIUrl":"https://doi.org/10.35479/ijretina.2021.vol004.iss002.156","url":null,"abstract":"Introduction :  Diabetic Retinopathy (DR) is one of the major cause of visual acuity deterioration in diabetic patients. The loss of central visual acuity in diabetic patients are mainly due to macula edema, which is found in 29% diabetic patients with the over 20 years duration of disease. The aim of this study is to evaluate and investigate the possible correlation among changes of visual acuity (VA), central macular thickness (CMT) using Spectral Domain Optical Coherence Tomography (SD-OCT). Electrophysiological responses using multifocal electroretinography (MfERG) in diabetic macular edema (DME) following intravitreal injection of bevacizumab. \u0000Methods: Single arm clinical trial. Thirty-three eyes of 33 DME patients (16 non-proliferative diabetic retinopathy and 17 non-high-risk proliferative diabetic retinopathy), receives intravitreal bevacizumab 1,25mg. All patients underwent complete ophthalmic examination including ETDRS VA testing, Sixty-one scaled hexagon MfERG and SD-OCT scan at baseline, 1-week and 1-month post-injection. Components of the first order kernel (N1, N2 and P1) in central 2o were measured. \u0000Result : MfERG showed reduced P1 amplitude (P<0.05) at 1-week after injection followed by increased P1 amplitude (P>0.05) at 1-month after treatment as compared to the baseline in all subjects. There was 19% improvement CMT and 0.2Logmar VA improvement in 1-month post-injection compared to the baseline (P<005). This study showed no serious ocular adverse effects. There was no significant correlation between changes in visual acuity with changes in CMT or other MfERG parameters. \u0000Conclusion: Intravitreal injection bevacizumab resulting in improved VA, reduction in CMT and mild improvement in the MfERG responses. Although VA changes did not correlate with reduced CMT nor with improved responses of MfERG, the combined use of SD-OCT and MfERG may be used to evaluate macular function in DME patient with worsened visual acuity post anti-VEGF injection.","PeriodicalId":33128,"journal":{"name":"IJRETINA International Journal of Retina","volume":"101 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87937823","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Prospective Study of Safety Profile and Efficacy of three doses of Intravitreal Bevacizumab in Diabetic Macular Edema","authors":"Nasrin Y, S. Ajay, Sharmila Yalakala","doi":"10.35479/ijretina.2021.vol004.iss002.171","DOIUrl":"https://doi.org/10.35479/ijretina.2021.vol004.iss002.171","url":null,"abstract":"Introduction: Current study aimed to evaluate efficacy of intravitreal Bevacizumab in Diabetic macular edema, and to identify their ocular and systemic complications if any. \u0000Method: It is a prospective, interventional study with 68 patients in 82 eyes with Diabetic macular edema. All treated by 3 injection of intravitreal bevacizumab with 1 month interval. Visual acuity, macular edema, and complications evaluated at every month upto 6th months. Ranibizumab was offered if the patient is a non-respondent to Bevacizumab. \u0000Results: Majority age group of 61-70 years with a mean age of 59 ± 6.72 years. The mean duration of diabetes was 11.68 ± 7.2 years. The mean baseline BCVA and CRT are 0.64 ± 0.28 Log MAR units and 436.99 ± 135.10 μm. After 3 injections, BCVA values are 0.48±0.27 (p< 0.01)), 0.36±0.24 (p<0.01)), and 0.27±0.24 (p<0.01), 0.23±0.27 Log MAR (p<0.01)) at 1month, 2 months, and 3 months, and 6 months follow-up respectively. CMT levels are 315.79±124.60 μ at 1 month, after 3rd IVA and this significant change (p<0.01) followed with subsequent follow-up with mean CRT of 296.04±122.97 μ (p< 0.01) at 6th month. The BCVA improved ≥ 2 Snellen lines in 69.5% and 78% cases, resolution of CMT in 56% and 69.5% cases at 3 months and 6 months respectively. At the end of the 3rd month, 46 eyes macular edema completely resolved with 3 injections of IVA, 23 eyes persistent macular edema present, 13 eyes refractory to bevacizumab injections. Persistent & Refractory macular edema eyes (36) switched to Ranibizumab injections.In persistent macular edema, significant resolution (p≤0.01) of macular thickness (370.52 ± 71.43 µm vs. 341.08 ± 122.75 µm) without (p=0.09) improvement in visual acuity (0.45 ± 0.20 vs. 0.34 ± 0.23) was observed post Ranibizumab injections.  In Refractory macular edema, thickness of cases no significant (497.76 ± 161.07µm vs 407.84 ± 169.64 µm) improvement seen after Ranibizumab injections(p=0.1). Recurrence of macular edema seen in 10.9%. Subconjunctival haemorrhage seen in 10.9%-12.1% cases, raised IOP in 2.4%-3.6% cases at post injection day 1. No other ocular and systemic complications were observed during follow-up. \u0000Conclusions: Intravitreal bevacizumab is effective in treatment of diabetic macular edema but therapeutic effect is temporary and repeat treatment is needed. It does not show any potential drug related ocular and systemic side effects, hence it is safe and economical therapeutic agent","PeriodicalId":33128,"journal":{"name":"IJRETINA International Journal of Retina","volume":"29 2 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76006403","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"DIFFERENCES OF APOLIPOPROTEIN A1 AND APOLIPOPROTEIN B LEVELS IN TYPE 2 DIABETES MELLITUS (T2DM) PATIENTS WITH DIABETIC RETINOPATHY AND WITHOUT DIABETIC RETINOPATHY","authors":"Shabrina Hanifah, A. N. Agni, I. Mahayana, Suhardjo Suhardjo, T. Triyono","doi":"10.35479/ijretina.2021.vol004.iss002.153","DOIUrl":"https://doi.org/10.35479/ijretina.2021.vol004.iss002.153","url":null,"abstract":"Introduction Apolipoprotein A1 are antiatherogenic in blood serum and have an anti-inflammatory while Apolipoprotein B describes a protein structure that is potentially atherogenic.. Meanwhile, the inflammatory process plays a role in the diabetic retinopathy process. The aim of this study was to determine whether there were differences in the levels of apolipoprotein A1 and B in diabetic retinopathy patients and without diabetic retinopathy. \u0000Methods: This study used a cross sectional design. The subjects of this study were type 2 diabetes mellitus patients with diabetic retinopathy and without diabetic retinopathy at Dr. Sardjito General Hospital from July to September 2020. Subjects consisted of 32 patients in the group with diabetic retinopathy and 31 patients without diabetic retinopathy. The levels of apolipoprotein A1 and apolipoprotein B were analyzed using independent T test. The factors affecting apolipoprotein A1 and apolipoprotein B were analyzed using multiple regression tests. \u0000Result: There were no significant differences (p> 0.05) in age, gender, duration of diabetes, HDL, triglycerides, HbA1c, BMI, physical activity, and smoking history. The mean apolipoprotein A1 level in the diabetic retinopathy group was 1.46 ± 0.177 mg / dL higher than the non-diabetic retinopathy group, namely 1.44 ± 0.27 mg / dL (p = 0.699). The mean level of apolipoprotein B in the diabetic retinopathy group was 1.26 ± 0.289 mg / dl higher than the non-diabetic retinopathy group 1.01 ± 0.26 mg / dL (p = 0.001). The mean LDL levels were 162.5 ± 48.38 mmol / L in the diabetic retinopathy group and 127 ± 38.45 mmol / L in the group without diabetic retinopathy (p = 0.012). \u0000Conclusion: Apolipoprotein B levels were found to be higher in the group with diabetic retinopathy than in the group without diabetic retinopathy and there was a significant difference between the two assumed due to an atherogenic  process in the diabetic retinopathy group. Further research is needed to assess the causal relationship between elevated levels of Apo B and the incidence of diabetic retinopathy by calculating the ratio of apolipoprotein B to apolipoprotein A1. \u0000Keywords: Apolipoprotein A1, Apolipoprotein B, Diabetic Retinopathy","PeriodicalId":33128,"journal":{"name":"IJRETINA International Journal of Retina","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86578583","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"ASSOCIATION BETWEEN CENTRAL RETINAL THICKNESS AND VISUAL OUTCOME POST INTRAVITREAL RANIBIZUMAB INJECTION LOADING DOSES IN EXUDATIVE AGE RELATED MACULAR DEGENERATION","authors":"Ferdian Ramadhan, Ima Yustiarini, Ady Dwi Prakosa, Sauli Ari Widjaja, Wimbo Sasono, Muhammad Firmansjah","doi":"10.35479/ijretina.2021.vol004.iss002.169","DOIUrl":"https://doi.org/10.35479/ijretina.2021.vol004.iss002.169","url":null,"abstract":"Introduction : Age Related Macular Degeneration (AMD) stills the leading cause of blindness in developing countries for age 50 and above, increasing along higher life expectations.Anti- VEGF is the mainstay management for exudative AMD and able to reduce the central retinal thickness (CRT) and to increase the visual outcome. The aim of this study is to correlate between CRT and visual outcome in exudative AMD post intravitreal ranibizumab injection loading doses in Soetomo general academic hospital, Surabaya \u0000Methods : This was a retrospective, cross sectional study. Fourty two eyes who met inclusion criterias were received monthly loading doses of 0.5 mg Ranibizumab intravitreal injection for three consequtives months. Baseline visual acuity (BCVA) was measured with Snellen Chart converted to LogMAR, CRT was measured by SD-OCT. Parameters was measured before the first injection and after completed three months injections. \u0000Result : Fourty two eyes were composed by 59.5% male and 40.5% female with higher incidence in 61-70 years old (47.6%). Mean BCVA were 0.831 before and 0.624 after injection of serial Ranibizumab. Mean CRT were 346.9 and 254.2 µm before and after injection respectively. There was significant comparison between CRT and BCVA (p=0.00) & no correlation between CRT and BCVA before and after injection of Ranibizumab loading doses (p=0.418 & p=0.275) \u0000Conclusion : There were no correlation statistically between CRT and BCVA before and after injection of loading doses Ranibizumab intravitreal in exudative AMD. Further studies may be needed to prove the etiology of this tendencies.","PeriodicalId":33128,"journal":{"name":"IJRETINA International Journal of Retina","volume":"67 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80968795","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}